<SEC-DOCUMENT>0001015820-16-000045.txt : 20160111
<SEC-HEADER>0001015820-16-000045.hdr.sgml : 20160111
<ACCEPTANCE-DATETIME>20160111074627
ACCESSION NUMBER:		0001015820-16-000045
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160131
FILED AS OF DATE:		20160111
DATE AS OF CHANGE:		20160111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QIAGEN NV
		CENTRAL INDEX KEY:			0001015820
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-28564
		FILM NUMBER:		161335068

	BUSINESS ADDRESS:	
		STREET 1:		SPOORSTRAAT 50
		CITY:			KJ VENLO
		STATE:			P7
		ZIP:			5911
		BUSINESS PHONE:		31-77-320-8400

	MAIL ADDRESS:	
		STREET 1:		SPOORSTRAAT 50
		CITY:			KJ VENLO
		STATE:			P7
		ZIP:			5911
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>jan2016pr.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>6-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sbd19485dff314704809a5300bbf7cdd2"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;__________________________________</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 6-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;__________________________________</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Report of Foreign Private Issuer</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Rule 13a-16 or 15d-16 under</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the month ended</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">January 31, 2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number 0-28564</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;__________________________________</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">QIAGEN N.V.</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;__________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Spoorstraat 50</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5911 KJ Venlo</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Netherlands</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;__________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form 20-F&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="sd64caf76540a493a9293d5828ea6fa04"></a><div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QIAGEN N.V.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form 6-K</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="82%"></td><td width="18%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Item</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Information</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd51981a5290741deb87c7d6f2a8ce20a"><font style="font-family:inherit;font-size:10pt;">3</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signatures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s73d363304d704c62859184b0200b8e18"><font style="font-family:inherit;font-size:10pt;">4</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s00d50a4b2e83427b8ccbf85f32a3daae"><font style="font-family:inherit;font-size:10pt;">5</font></a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="sd51981a5290741deb87c7d6f2a8ce20a"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd64caf76540a493a9293d5828ea6fa04"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On January 10, 2016, QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) issued press releases announcing preliminary results for full-year 2015 and first guidance for 2016.&#160; The press releases are furnished herewith as Exhibit 99.1 and Exhibit 99.2 and are incorporated by reference herein.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:44px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:44px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:44px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s73d363304d704c62859184b0200b8e18"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd64caf76540a493a9293d5828ea6fa04"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="8%"></td><td width="46%"></td><td width="46%"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QIAGEN N.V.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Roland Sackers</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roland Sackers</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  January 11, 2016</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s00d50a4b2e83427b8ccbf85f32a3daae"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd64caf76540a493a9293d5828ea6fa04"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="17%"></td><td width="7%"></td><td width="76%"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-align:center;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">Exhibit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release dated January 10, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ad Hoc Release dated January 10, 2016</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="sde265b031abc43c6935efcb5250ce060"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd64caf76540a493a9293d5828ea6fa04"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 99.1</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="qgennewheaderlogoa09.jpg" style="height:82px;width:640px;"></div></td></tr></table></div></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:15pt;"><font style="font-family:Arial;font-size:15pt;font-weight:bold;">QIAGEN announces preliminary results for full-year 2015 </font></div><div style="line-height:120%;text-align:center;font-size:15pt;"><font style="font-family:Arial;font-size:15pt;font-weight:bold;">and provides 2016 outlook </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">VENLO, the Netherlands, January 10, 2016</font><font style="font-family:Arial;font-size:11pt;">&#32;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">-</font><font style="font-family:Arial;font-size:11pt;">&#32;QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the fourth quarter and full-year 2015 and provided an outlook for 2016. The preliminary results for 2015 are unaudited and based on management&#8217;s preliminary financial analysis and may be adjusted as a result of, among other things, completion of customary financial close review and audit procedures. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#8220;Our anticipated results for the fourth quarter of 2015 are disappointing given the shortfall against our expectations for more improvements in adjusted net sales and adjusted earnings per share compared to the same period in 2014. This performance was hampered by factors that included volatility in the timing of revenues from the growing portfolio of companion diagnostic partnerships as well as lower revenues from instruments, even though we exceeded our target for new placements of QIAsymphony automation systems. Despite this setback, and due to the nature of these factors, QIAGEN continues to have a solid outlook for accelerating growth in 2016 based on the progress made on key initiatives during 2015. These included higher sales to Life Science customers, ongoing double-digit sales growth for the QuantiFERON-TB and bioinformatics franchises as well as the launch of the GeneReader NGS System in late 2015,&#8221; said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. &#8220;Our current expectations for 2016 are for approximately 6% adjusted net sales growth at constant exchange rates (CER), and for adjusted earnings per share at CER to grow approximately in line with sales.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Preliminary full-year and fourth quarter 2015 results</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">For the full-year 2015, adjusted net sales are estimated to have risen approximately 3% at constant exchange rates (CER) compared to 2014 (QIAGEN had previously communicated an outlook for approximately 4% CER growth), but to have declined about 5% at actual rates to approximately $1,280 million due to about eight percentage points of adverse currency movements of the U.S. dollar, QIAGEN&#8217;s reporting currency, against various other currencies. About two percentage points of total CER growth are estimated to have come from the acquisitions of the Enzymatics NGS technology and consumables portfolio (acquired in December 2014) and the BIOBASE bioinformatics business (acquired in April 2014), while sales in the rest of the business are expected to have provided about one percentage point. Excluding the impact of lower U.S. sales of Human Papilloma Virus test products (cervical cancer screening), which created approximately three percentage points of headwind, adjusted net sales are estimated to have risen about 6% CER compared to 2014. Adjusted diluted earnings per share (EPS) are expected to have been approximately $1.13-$1.14 CER for the full year compared to $1.00 in 2014 (QIAGEN had previously communicated an outlook for adjusted diluted EPS of $1.16 CER). Adjusted diluted EPS results at actual rates are expected to have been approximately $1.05-$1.06 and reflecting the impact of adverse currency movements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">For the fourth quarter of 2015, adjusted net sales are estimated to have risen approximately 3% at constant exchange rates (CER) compared to the fourth quarter of 2014 (QIAGEN had previously communicated an outlook for approximately 5% CER growth), but to have declined approximately 3% at actual rates to approximately $348 million due to about six percentage points of adverse currency movements. About two percentage points of total CER growth are estimated to have come from the acquisitions of the Enzymatics NGS portfolio (acquired in December 2014), while sales from the rest of the business are expected to have </font></div><br><div><div style="line-height:120%;"><img src="qiagenfootera07.jpg" style="height:42px;width:640px;"></div></div><hr style="page-break-after:always"><a name="sde265b031abc43c6935efcb5250ce060"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd64caf76540a493a9293d5828ea6fa04"><font style="font-family:inherit;font-size:10pt;">Table of contents</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="qgennewheaderlogoa09.jpg" style="height:82px;width:640px;"></div></td></tr></table></div></div></div><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">provided about one percentage point compared to the fourth quarter of 2014. Late in the fourth quarter of 2015, QIAGEN completed the acquisition of MO BIO Laboratories Inc., a leader in sample technologies for microbiomes, but this had a negligible contribution to results. Excluding the impact of lower U.S. sales of HPV tests, which created approximately one percentage point of headwind, adjusted net sales are estimated to have risen approximately 4% CER compared to the year-ago period. Adjusted diluted earnings per share (EPS) are expected to have been approximately $0.33-$0.34 CER compared to $0.25 in the fourth quarter of 2014 (QIAGEN had previously communicated an outlook for adjusted diluted EPS of $0.35 CER). Adjusted diluted EPS results at actual rates are expected to have been approximately $0.31-$0.32 and reflect the impact of adverse currency movements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QIAGEN confirms its previously announced plans to report full financial results for the fourth quarter and full-year 2015 on Tuesday, February 2, at approximately 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). A conference call is planned for Wednesday, February 3, starting at 15:30 CET / 9:30 ET. Further information is available at www.qiagen.com/de/about-us/investors/corporate-calendar.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Outlook for full-year 2016</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QIAGEN announced today its outlook for the full-year 2016, with expectations for adjusted net sales to rise approximately 6% CER from the current portfolio (including anticipated incremental contributions of less than one percentage point from 2015 acquisitions). These expectations do not take into account any further acquisitions that could be completed in 2016. Adjusted diluted earnings per share (EPS) for the full-year 2016 at CER are expected to rise approximately in line with sales. Based on exchange rates as of January 8, 2016, QIAGEN currently expects currency movements against the U.S. dollar to have an adverse impact of approximately two percentage points for the full-year 2016 on results for adjusted net sales and adjusted diluted EPS at actual rates.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">QIAGEN to present at J.P. Morgan Healthcare Conference</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QIAGEN will participate at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 12, 2016. Peer Schatz, Chief Executive Officer, will present at 11:00 Pacific Time (PT) / 14:00 ET / 20:00 CET, with a question and answer session scheduled immediately following the presentation. A live webcast and audio archive will be available at this link: </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19947</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Use of adjusted results</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight into its performance.  For 2015, these results include adjusted net sales, (includes all revenue contributions from bioinformatics acquisitions), adjusted gross profit, adjusted operating income, adjusted net income attributable to owners of QIAGEN N.V., adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures that QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. Free cash flow is calculated by deducting capital expenditures for Property, Plant &amp; Equipment from cash flow from operating activities. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its </font></div><br><div><div style="line-height:120%;"><img src="qiagenfootera07.jpg" style="height:42px;width:640px;"></div></div><hr style="page-break-after:always"><a name="sde265b031abc43c6935efcb5250ce060"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd64caf76540a493a9293d5828ea6fa04"><font style="font-family:inherit;font-size:10pt;">Table of contents</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="qgennewheaderlogoa09.jpg" style="height:82px;width:640px;"></div></td></tr></table></div></div></div><br><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">competitors and its own prior periods. Reconciliations will be included in the tables accompanying QIAGEN&#8217;s full financial results for the fourth quarter and full-year 2015.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">About QIAGEN</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2015, QIAGEN employed approximately 4,500 people in over 35 locations worldwide. Further information can be found at </font><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">http://www.qiagen.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results for the quarter and year ended December 31, 2015 and the year ending December 31, 2016, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">###</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Contacts:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">QIAGEN</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="25%"></td><td width="22%"></td><td width="26%"></td><td width="27%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Investor Relations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Public Relations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">John Gilardi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">+49 2103 29 11711</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Dr. Thomas Theuringer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;+49 2103 29 11826</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">e-mail: </font><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">ir@QIAGEN.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">e-mail: </font><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">pr@QIAGEN.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;"><img src="qiagenfootera07.jpg" style="height:42px;width:640px;"></div></div><hr style="page-break-after:always"><a name="sfc46cfa476934adfa9e12fb6d7546f49"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd64caf76540a493a9293d5828ea6fa04"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 99.2</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="qgennewheaderlogoa09.jpg" style="height:81px;width:625px;"></div></td></tr></table></div></div></div><br><div style="line-height:174%;padding-bottom:9px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Ad-hoc Announcement according to &#167; 15 WpHG</font></div><div style="line-height:174%;padding-bottom:9px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">QIAGEN N.V. announces preliminary results for full-year 2015 and provides 2016 outlook </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">For the full-year 2015, QIAGEN estimates adjusted net sales to have risen approximately 3% at constant exchange rates (CER) compared to 2014 (QIAGEN had previously communicated an outlook for approximately 4% CER growth), but to have declined about 5% at actual rates to approximately $1,280 million due to about eight percentage points of adverse currency movements of the U.S. dollar, QIAGEN&#8217;s reporting currency, against various other currencies. About two percentage points of total CER growth are estimated to have come from the acquisitions of the Enzymatics NGS technology and consumables portfolio (acquired in December 2014) and the BIOBASE bioinformatics business (acquired in April 2014), while sales in the rest of the business are expected to have provided about one percentage point. Excluding the impact of lower U.S. sales of Human Papilloma Virus test products (cervical cancer screening), which created approximately three percentage points of headwind, adjusted net sales are estimated to have risen about 6% CER compared to 2014. Adjusted diluted earnings per share (EPS) are expected to have been approximately $1.13-$1.14 CER for the full-year compared to $1.00 in 2014 (QIAGEN had previously communicated an outlook for adjusted diluted EPS of $1.16 CER). Adjusted diluted EPS results at actual rates are expected to have been approximately $1.05-$1.06 and reflecting the impact of adverse currency movements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">For the fourth quarter of 2015, adjusted net sales are estimated to have risen approximately 3% at constant exchange rates (CER) compared to the fourth quarter of 2014 (QIAGEN had previously communicated an outlook for approximately 5% CER growth), but to have declined approximately 3% at actual rates to approximately $348 million due to about six percentage points of adverse currency movements. About two percentage points of total CER growth are estimated to have come from the acquisitions of the Enzymatics NGS portfolio (acquired in December 2014), while sales from the rest of the business are expected to have provided about one percentage point compared to the fourth quarter of 2014. Late in the fourth quarter of 2015, QIAGEN completed the acquisition of MO BIO Laboratories Inc., a leader in sample technologies for microbiomes, but this had a negligible contribution to results. Excluding the impact of lower U.S. sales of HPV tests, which created approximately one percentage point of headwind, adjusted net sales are estimated to have risen approximately 4% CER compared to the year-ago period. Adjusted diluted earnings per share (EPS) are expected to have been approximately $0.33-$0.34 CER compared to $0.25 in the fourth quarter of 2014 (QIAGEN had previously communicated an outlook for adjusted diluted EPS of $0.35 CER). Adjusted diluted EPS results at actual rates are expected to have been approximately $0.31-$0.32 and reflecting the impact of adverse currency movements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">For the full-year 2016, QIAGEN expects adjusted net sales to rise approximately 6% CER from the current portfolio (including anticipated incremental contributions of less than one percentage point from 2015 acquisitions). These expectations do not take into account any further acquisitions that could be completed in 2016. Adjusted diluted earnings per share (EPS) for the full-year 2016 at CER are expected to rise approximately in line with sales. Based on exchange rates as of January 8, 2016, QIAGEN currently expects currency movements against the U.S. dollar to have an adverse impact of approximately two percentage points for the full-year 2016 on results for adjusted net sales and adjusted diluted EPS at actual rates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;"><img src="qiagenfootera07.jpg" style="height:42px;width:640px;"></div></div><hr style="page-break-after:always"><a name="sfc46cfa476934adfa9e12fb6d7546f49"></a><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sd64caf76540a493a9293d5828ea6fa04"><font style="font-family:inherit;font-size:10pt;">Table of contents</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="qgennewheaderlogoa09.jpg" style="height:82px;width:640px;"></div></td></tr></table></div></div></div><br><div style="line-height:174%;padding-bottom:9px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:174%;padding-bottom:9px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QIAGEN N.V.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Hulsterweg 82</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">5912 PL </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Venlo, </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">The Netherlands </font></div><div style="line-height:174%;padding-bottom:9px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:9px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">ISIN: NL0000240000</font></div><div style="line-height:174%;padding-bottom:9px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:9px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Frankfurt Stock Exchange, Regulated Market (Prime Standard)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;"><img src="qiagenfootera07.jpg" style="height:42px;width:640px;"></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>qgennewheaderlogoa09.jpg
<TEXT>
begin 644 qgennewheaderlogoa09.jpg
M_]C_X  02D9)1@ ! 0$       #_[@ .061O8F4 9      !_^$ %D5X:68
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M P,# P,#_\  $0@ : ,@ P$1  (1 0,1 ?_$ !T  0 " @(#
M   ("08' 0H#! 7_Q  Z$  ! P,"!0,# P(#" ,      P0% 08' @@3UA>7
M6!$4"2$C%1(S%C%!(D,D4<%38Y,TA HF&$C_Q  = 0$  P # 0$!
M    !08' P0( @$)_\0 5!$!  $" @4) P4*"0D)      ,$!0$"$1,4!@<A
M$B.CTU25%U<Q,PA!42*#%6&!D3)#4V-S)!;P<:'!0I,T1 FQX6*"DK*S9#71
M\5)RPH24577_V@ , P$  A$#$0 _ ._P
M
M
M
M
M
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M#ER\R?YOG;$(9,
M
M&J<JVNK<$8V>-ED$G$-I=JUHZ51;H:VCC0E5S^IPXUZ4$:IZFVC5ZZ_\)8-W
M;K%;:O')488ZB7###'Y?9_WJ_O#;)*ZEPDB_&CY6IL6VRG.2>B:1DX1]%QFM
MPBKJAYN-F=>MYK352JUJK%.WB"%4*5^Y13ZU_L6?>6[[)1['JY]IE_.Q:O\
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MO3=&FT-4G;GYG53B:6'\DATY!1M_7W7XKW?YS@?^,3OVU2[!]HZN;9OU4O\
MQ/=]8B?LFJVW[/TP[1^MCT_@]XSO)-ETB(^/F:2D<A&Q<4PBI!S+R#"(2T:V
MB=4DG7N)-9%EZ+>G[55*?4@K!?-?GEI<8\<:F:?6]%AC)CR_)HT?)\^A+7NR
M2Q11RPR?L\,&K9-AZV%&>E2Y57;)PG(,O:L/QS]I(M];;4HBLLK5PQ5<,ZUU
M*(Z/3AZZT^A'[SW>"KQRT$&&/-BQ^7#'#'YO9CAAC\ORN[NS;9J;#&LET:9<
M&]BHK<
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MS\S'ZQ8N$]3785U328_],PBP^]+IPT8_Z^3G_P!6N:/.C<P
M
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M_4%38I:*&@O-+AA+HAT\RHC]WCG^GIEZ/Z&&.LDDQT9X_I_(OG/-;TD
M
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M9*VFH*^HPY,=&CF1TV,>,FG#ECUG,P_.8+%M]7Q 6MN7IAY79/G3%%TWSAC
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M4DF,$L<&>FRXY9,^HFDCR99^=CFBS9]7IR9,N,7RXZ78%/.S<P
M
M                                0S<9RW2).%DF^R"ZWB":ZNA%UISQ
M@QO1=/0I^E)Q5%6XZ+(T62I_2OU(G-5W33_8<?ZV-ND'#G@W)'TW$2BBQ_\
MQKQ_-"XZ[;JO!>[._P#@GF8^-NN7<>MC??EMP:]1Z+P:\]BDMCF<NJY+-AYJ
M];&=XVN9[61_)V4^GX&Z'<+[:6?-&?&G;9<.X1]61CT$G=. IJX=%Z)ZZ\31
MJH2D.?/GBPSR9-7GQ]N7YOX>UDV\UNLEIO<UOW=N.6[6>+"/".JRPRT^$NF/
M)CGT13]+DU<F.:+Z?+FYG.PY,V"C[YS;GF9)SL9V\7%>,CCG;EN+W"(VQN(O
M1C(5B&Z-N0\M8R4/ 3,G^O0BWB7J%QR4E7W-?9)+Q";A?[;>I5-[),V;9:/-
M+JJ66;1)C]SD?T/_ ,.JTV^BR<1.*MKH(;KQ7W2W8QJ;'2R1ZW]HDCJ\9:B.
M/VXR9,8((,.9TN.6IS1Y.617_P#*7BWX^=E<59[W9S,__7W?5@&Y[!N"TH*S
MG>1EI^Y[4EE=+5RK.O;I7=P=Q<=A+^XJ[3<.WDDEI<,W%%VZCBB<)?H++:L-
M-MZ&YQ:/SO\ G>FO@SWR^)_XA*^NI./%+^\WPW[ST5=%4RU45#J*>HC[OL^$
M<E/TD>KU?,CCIY-741ZN3)DY^A<:[JW^V_;#\RMU54_C^4,R;H:XDM&-T*:=
M+AA=&2)C+U+L4:5_4JX;.;5M!&7=)*^E?]8@W_IQ#ITU?L=!<N\RSZK_ (K2
M=\."U)Q8XQ\ ;/C^U[DV/<O[3J9?SE/1Q6O9_P#Y%1LV22/\W))^;12Q/N5E
M=@UI;IL,[?LV1^0*;A-JF))R&N^PI1:0I8^:$_XM7++"+?M-+/\ !O[/M">O
ME)%\FDB\X3*+<_N)T.E2W"6U1U,5')RS01?UG\-9BVO?;A+0?$O>=SN(7$_=
M^:T_NGOI=(I::NBU>V6K]J^RY)(_RD=141V?]GZ2/GR5D?NUG5Z;0/C<PK\=
M.W_)]V;8<_;D:Y7QDSOG(FY';MK?SEUXYG=$!$3UTW'<\K(3W\'L*WF,K).8
MY)K(L56B-62B;Q-1VFHX)G-;K-!9J>;&*>76P^]B_)X?>Z/[CQ_N[QU^+#B!
M\5>].Y]GWRW8W3PL=ZDIJ&QWS"..GKX];+3T]/3Y(XMLK*B2...HSR4\D<DF
M,D<E/JX]7'A")M<,!NVWX,[LQ'LJO7=U:,AM8LMM:F$<ZY1I9=^LX#'["U<?
M-LC71??YY[^;D:I07$25J]66DFDPFX4^X1N7&.X73H:;7=![J65Z#S6JZ<$?
MANEL&^N_ULW(O46^E5M-WL]!ME'M%9M59]GT]'JOV>/I/S<>SR4^K97<FC<S
MM^W]9VW1;?,1-<82FS[#VTB9R_ME:7&ZN-&(Q'<&V_$L%>^.E9EG21I<L!:J
M#)-)TZ]%UF=$4Y1/[C.GIRYL:^BNDE;1Y-5LD,6LBT_D]5'R?P^;^-#VK'A!
MQ-^&/=O@QQ/O?VM3;^7K>B*V[P8Q;/K+I3WZZ5%'<-7T>SU%1K.CC_*ZS8Y.
MBJ.6U[X0LL6MGK=?\KF:[+_):;7R;D7!=XP*,HA5F^;QT^YSV^3:/VM%%M&A
M\RK7@ZZZ=>M.NK16J>JM*UJ63=6IR5E=<*J/\7/GCS?[6L_['BW_ !#MRKOP
MTX,\%.'E_P!3FO5GL]WI9<T>.&?)FSPY;)DS9LF?V\S-HPQPYV.GDT8X89LN
M;!V!<A3]U6Q9\O.V38KK)5SL?8?C+*93\):[J:HYE&31[PIVXUF\,Q_&QSA9
MW7C:]/%TH53T>NO7IH6^;/)'%CGBR\^3#V9=.C3]_E?S*W7MMEN]]@MV\-QR
M6FT2XY]95YX)JC+%HCS9LFF&GRYI<^&?/AEC^AEQYO/Y^;Z.7,C/7.VZJO\
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M%-'45>:HCHXYIZW&2HFBSSY]CCSXXT\5-'S\\O1\W')ER3Q)9YO
M
M
M
M
M
M
M
4                       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>qiagenfootera07.jpg
<TEXT>
begin 644 qiagenfootera07.jpg
M_]C_X  02D9)1@ ! 0$       #_[@ .061O8F4 9      !_^$ %D5X:68
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M9&8Z4D1&/@T*/"]X.GAM<&UE=&$^#0H\/WAP86-K970@96YD/2=W)S\^_]L
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M 0 "$0,1 #\ _?P
M
M
M
M
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M2*_N_P"A*R F
M
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M+;C!2J2DXP3;?BFDW\O%_)H,IRV
M
M
M
M
M
M
:                               !_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
